Targeting the Flavivirus Envelope Protein to Fight Dengue and Zika Viruses
Validating the Flavivirus Envelope Protein as an Antiviral Target
This study is looking for new medicines to help fight dengue and Zika viruses by finding ways to stop the viruses from entering human cells, and it's aimed at anyone concerned about these illnesses.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-10798141 on NIH RePORTER |
What this research studies
This research focuses on developing new antiviral treatments for dengue and Zika viruses by targeting the flavivirus envelope protein. The approach involves identifying small molecule inhibitors that can block the viral entry process, which is crucial for the viruses to infect human cells. By using advanced computational models and in vivo evaluations, the researchers aim to validate these inhibitors and assess their effectiveness against these significant public health threats. The goal is to create broad-spectrum antiviral agents that can be used against multiple flavivirus strains.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk of dengue or Zika virus infections, particularly those living in endemic areas.
Not a fit: Patients who are not at risk for dengue or Zika virus infections, such as those living in non-endemic regions, may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of effective antiviral drugs that prevent or treat infections caused by dengue and Zika viruses.
How similar studies have performed: Previous research has shown promise in targeting viral envelope proteins for antiviral development, indicating potential success for this novel approach.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Yang, Priscilla Li-Ning — Stanford University
- Study coordinator: Yang, Priscilla Li-Ning
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.